BCL-XL Inhibitor A-1155463: Potent, Selective Apoptosis Induction Tool

Executive Summary: BCL-XL inhibitor A-1155463 (SKU B6163) is a small molecule that selectively targets the anti-apoptotic protein BCL-XL, demonstrating high binding affinity (Ki = 19 nM) and robust in vitro and in vivo efficacy (Koessinger et al. 2022). It induces apoptosis in BCL-XL-dependent cancer cells, outperforming earlier inhibitors such as WEHI-539. In preclinical mouse models, A-1155463 causes transient platelet depletion and significant tumor growth inhibition at 5 mg/kg intraperitoneal dosing. The compound is insoluble in water and ethanol but highly soluble in DMSO (≥67 mg/mL), with recommended storage at -20°C. APExBIO supplies A-1155463 for advanced research in hematological malignancies and solid tumor models (APExBIO).

Biological Rationale

The BCL-2 family of proteins regulates the intrinsic (mitochondrial) apoptosis pathway, balancing cell survival and programmed cell death (Koessinger et al. 2022). Anti-apoptotic members, such as BCL-XL and MCL-1, are frequently overexpressed in hematological malignancies and solid tumors, contributing to drug resistance and tumor persistence. Glioblastoma and other aggressive cancers have been shown to require BCL-XL for survival, making selective BCL-XL inhibition a rational therapeutic strategy. Targeting BCL-XL with selective inhibitors like A-1155463 can restore apoptotic sensitivity, particularly in tumors with high apoptotic priming or resistance to conventional treatments. This approach enables researchers to dissect apoptotic dependencies and develop combination therapies that overcome resistance mechanisms.

Mechanism of Action of BCL-XL inhibitor A-1155463

A-1155463 binds selectively and with high affinity (Ki = 19 nM) to the hydrophobic groove of the BCL-XL protein, a key anti-apoptotic regulator in the BCL-2 family (Koessinger et al. 2022). By occupying this site, A-1155463 disrupts the interaction between BCL-XL and pro-apoptotic BH3-only proteins, such as BIM and BAD. This displacement enables the activation of BAX/BAK, leading to mitochondrial outer membrane permeabilization (MOMP), cytochrome c release, and caspase activation. The net effect is the induction of apoptosis specifically in cells that are dependent on BCL-XL for survival. Unlike dual BCL-2/BCL-XL inhibitors (e.g., navitoclax), A-1155463 is highly selective, thereby reducing off-target effects on BCL-2 and minimizing unwanted cytotoxicity in non-target tissues.

Evidence & Benchmarks

• A-1155463 exhibits a binding affinity (Ki) of 19 nM for BCL-XL, as determined by nuclear magnetic resonance and structure-guided design (Koessinger et al. 2022, DOI).
• It demonstrates higher potency against BCL-XL-dependent cell lines than earlier inhibitors such as WEHI-539 (Koessinger et al. 2022, DOI).
• In SCID-Beige mice, 5 mg/kg intraperitoneal A-1155463 administration causes transient platelet depletion followed by recovery, confirming on-target BCL-XL inhibition (Koessinger et al. 2022, DOI).
• Daily dosing for 14 days significantly inhibits tumor growth in H146 xenograft models, with tumor progression resuming after cessation (Koessinger et al. 2022, DOI).
• Selective BCL-XL inhibition enables apoptosis induction in tumor models with high apoptotic priming, as seen in glioblastoma and hematological malignancies (Koessinger et al. 2022, DOI).
• For further discussion on assay integration and reproducibility, see Addressing Laboratory Challenges with BCL-XL inhibitor A-1155463, which this article extends by detailing in vivo benchmarks.
• This review updates the mechanistic focus provided in BCL-XL Inhibitor A-1155463: Unraveling the BCL-2 Family Pathway with new preclinical efficacy data.

Applications, Limits & Misconceptions

A-1155463 is optimized for research on apoptosis induction, tumor growth inhibition, and drug resistance mechanisms in BCL-XL-dependent models. Its selectivity allows for precise dissection of the BCL-2 family protein pathway and apoptotic signaling in preclinical settings. Key applications include:

• Apoptosis induction studies in hematological malignancies and solid tumors with high BCL-XL expression.
• Combination therapy research to overcome drug resistance in cancer cells.
• Preclinical evaluation of tumor growth inhibition using xenograft models.
• Investigation of platelet homeostasis and the hematological side effects of BCL-XL inhibition.

Common Pitfalls or Misconceptions

• Not effective in tumors lacking BCL-XL dependency: A-1155463 shows limited efficacy in cell lines or tumors where anti-apoptotic signaling is dominated by other BCL-2 family members such as MCL-1.
• Not suitable for long-term storage in solution: Solutions should be prepared fresh or used short-term, as compound stability declines over time at room temperature or above.
• Not water or ethanol soluble: Use DMSO (≥67 mg/mL) for stock preparation; attempts to dissolve in other solvents may result in precipitation or activity loss.
• Platelet toxicity risk: Like other BCL-XL inhibitors, transient thrombocytopenia is observed in vivo; this should be considered in experimental design.
• Not a clinical drug: A-1155463 is for preclinical research only and is not approved for human or veterinary therapeutic use.

For scenario-based assay and workflow guidance, Solving Lab Challenges with BCL-XL Inhibitor A-1155463 details integration strategies that this article expands by providing updated in vivo parameters and selectivity data.

Workflow Integration & Parameters

BCL-XL inhibitor A-1155463 (APExBIO, SKU B6163) is supplied as a solid and should be stored at -20°C. For in vitro assays, dissolve in DMSO at concentrations up to 67 mg/mL. Typical working concentrations range from 10 nM to 1 μM, depending on cell model and endpoint. For in vivo studies, intraperitoneal administration at 5 mg/kg in SCID-Beige mice has demonstrated efficacy and on-target activity. Always include controls for DMSO vehicle and, where appropriate, parallel BCL-2 or MCL-1 inhibition to differentiate pathway-specific effects. The product page (BCL-XL inhibitor A-1155463) provides chemical and handling specifications. For troubleshooting and protocol optimization, consult Addressing Laboratory Challenges with BCL-XL inhibitor A-1155463.

Conclusion & Outlook

A-1155463 is a best-in-class, selective BCL-XL inhibitor that enables advanced research on apoptosis, drug resistance, and tumor biology in BCL-XL-dependent models. Its potency, selectivity, and robust preclinical efficacy distinguish it from earlier generations. As research advances, A-1155463 will remain a valuable tool for dissecting the BCL-2 family protein pathway and supporting the development of rational combination therapies. Researchers are encouraged to integrate A-1155463 into preclinical workflows to probe apoptotic signaling and tumor response, leveraging its unique selectivity profile and rigorous product support from APExBIO.